Perrigo clindamycin

DUBLIN, Feb. 26, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ( Perrigo or the Company ), a leading provider of consumer health products, today announced financial results from continuing operations for the fourth quarter and fiscal year ended December 31, 2025. All comparisons are against the prior year fourth quarter and fiscal year, unless otherwise noted. Perrigo’s Unique Business Model Provides Opportunities in Current Macro Environment Opportunity for mid-tier and store brand share gains due to weakening consumer confidence U.S. OTC store brand share +50bps over the latest 4-weeks1 as consumers quickly adjust buying patterns Perrigo Announces Quarterly Dividend DUBLIN, Oct. 29, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of consumer health products, today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on December 16, 2025, to shareholders of record on November 28, 2025. Perrigo Announces Quarterly Dividend DUBLIN, Feb. 19, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of consumer products, today announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash dividend is payable on March 24, 2026, to shareholders of record on March 2, 2026. DUBLIN, April 30, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ( Perrigo or the Company ), a leading global provider of consumer health products, today announced that it has completed the previously announced sale of its branded Dermacosmetics business to Karo Healthcare ( Karo ) for total consideration of up to €332.6 million. The transaction consists of €305.6 million in. CORE Perrigo excludes the Infant Formula business and previously announced divestitures, primarily Dermacosmetics and exited products. Change in organic net sales excludes the effects of acquisitions, divestitures and exited products, and the impact of currency. Perrigo to Present at the UBS Global Consumer and Retail Conference FEB 26, 2026 Circana 4-week data displayed for each period, in the categories where Perrigo participates in cough cold, allergy, digestive health, pain, nicotine replacement, skin care and women’s health categories. Perrigo is centralizing and enhancing its global brand-building capabilities to deliver self-care solutions that consumers want—powered by deep insights, preferred innovation and impactful marketing. Execution will be driven by market-empowered activation, commercial go-to-market excellence and strong customer relationships. Perrigo's CEO John T. Hendrickson stated, Today's announcement is the result of Perrigo's review of strategic alternatives for the Tysabri® royalty stream announced in November 2016. We are pleased to have reached an agreement that maximizes the value of this non-core asset. While dilutive to adjusted EPS, the significant upfront cash component will allow us to de-lever our balance sheet.

Meta: